₹159 Crore Surge, But Platforms Still in Beta
Concord delivered strong revenue growth (+95% YoY) and upgraded order book to ₹846 Cr, but management overstated profit growth (claimed 95%, actual 80.2%) and kept guidance flat. The quarter is operationally solid, but the 40–50% CAGR story depends on executing Kavach approval, Fusion ramp, and hydrogen platforms that remain early-stage.
₹159 Cr
+95.1% YoY
~95%
on the call
80.2%
₹31.1 Cr vs ~₹17.3 Cr PY
29.3%
beat 20–25% prior guidance
On the earnings call, management highlighted profit growth at approximately 95%, aligning with revenue expansion. The delivered number tells a different story: PAT grew 80.2% YoY to ₹31.1 Cr, lagging the revenue surge by 15 percentage points. It's not a crater, but it is selective framing — the company nailing revenue and margin, but softening the profit narrative. Revenue and EBITDA, by contrast, are clean: ₹159 Cr (+95% organic), EBITDA margin at 29.3% beats prior guidance of 20–25%. Order book upgraded mid-year to ₹846 Cr, providing 4× annual revenue in backlog.
What the quarter actually was
Concord ran a textbook execution quarter: revenue delivery, margin expansion, working capital discipline, and a record order book. The company is on track for its stated 40–50% CAGR over the next 3–5 years, anchored by ₹846 Cr in orders spanning locomotives, Kavach safety systems, hydrogen propulsion, and Fusion PCB. Advanced Rail (locomotives + safety) now represents >80% of revenue; legacy Fusion (acquired earlier) is in production-ready state, targeting ₹400 Cr revenue at full scale. Debtor days improved to 178 from 210; inventory tightened from 313 to 259 days — railway projects are inherently long-cycle, so this is sound working capital management.
Revenue grown ~95% YoY to ~₹159 Cr
₹159.1 Cr, +95.1% YoY from ~₹81.6 Cr PY
Supported
Profits up ~95% to ₹31.2 Cr
₹31.1 Cr, +80.2% YoY, not 95%
Overstated by ~15pp
EBITDA margin 29.30%, up ~110% YoY
Margin 29.34%; prior EBITDA ~₹21 Cr, current ₹46.7 Cr
Supported
Order book ₹846 Cr as of 30-Sep-2026
Opening ₹697 Cr + received ₹308 Cr − executed ₹159 Cr = ₹846 Cr
Supported; mathematically verified
40–50% CAGR target over 3–5 years
H1 FY27 at 95% growth; ₹846 Cr backlog provides multi-year visibility
Supported by execution
Margins sustainable at 29–30% (vs prior 20–25% guidance)
Delivered 29.3%; no upside above 30% flagged by management
Floor solid; ceiling appears soft
What changed on this call
Order book upgraded. Mid-year jump from ₹697 Cr (FY-2026 guidance) to ₹846 Cr (+₹149 Cr, +21%) driven by new Kavach, hydrogen propulsion, and green-mobility orders. Margin beat. Delivered 29.3% vs prior guidance of 20–25%; economies of scale from order execution flowing through faster than expected. Fusion PCB production live. Backward integration complete for cost reduction; 30–40% of PCBA capacity initially utilized; target ₹400 Cr revenue at full scale by FY27–28. Hydrogen propulsion order in hand. ₹3,100 HP (horsepower) single order received; execution by next year, first deployment after battery locomotive success (running 12+ months).
Record order book (₹846 Cr) covers 3–4 years at current execution rate
EBITDA margin beat (29% vs 20–25% prior guidance); economies of scale showing
Railway electrification & green mobility are govt priorities (10+ year tailwind)
Fusion PCB backward integration de-risks cost and supply chain
PAT growth overstated (claimed 95%, actual 80.2%) — signals selective reporting
Kavach approval timeline vague; ISA cycle could slip 12–24 months
Hydrogen & battery propulsion platforms early-stage; execution risk high
80% of order book from Indian Railways; limited diversification
International expansion (FY30 target: 1/4–1/2 revenue) timeline uncertain
Kavach ISA approval slip
High₹100–120 Cr order book hinges on certification. Delay pushes revenue to FY28+, materially impacting CAGR trajectory.
Hydrogen propulsion execution risk
High₹3,100 HP order new; technology unproven at scale. Supply chain (fuel cell, tank) and integration risk could cause delays or cost overruns.
Customer concentration (80% Indian Railways)
HighRevenue dependent on govt buyer. Policy shift (e.g., electrification slowdown) or capex cuts would crater order flow.
Fusion PCB ramp-up slower than expected
MediumInitially 30–40% PCBA capacity; flex/rigid PCB market competitive. Underutilization or margin erosion could offset ₹400 Cr target.
EBITDA margin plateau at 29–30%
MediumNo upside flagged above 30%; economies of scale may offset inflation, but no expansion narrative beyond current level.
International partnerships take longer than FY30 target
Medium1/4–1/2 revenue from global by FY30 is aspirational; conversion from InnoTrans partnerships multi-year and unpriced.
How the street is positioned
The stock sits at ₹2,710 as of 2026-11-09, down 11.7% from its all-time high of ₹3,069.85 but still trading above its 20/50/200-day moving averages (₹2,526.60 / ₹2,389.76 / ₹2,479.56). RSI at 60.9 signals neutral positioning — neither overbought nor oversold. The drawdown coincides with either broader market weakness or platform-specific concerns; the position above key averages suggests a held baseline of confidence. Ownership remains promoter-heavy: 65.57% promoter vs FII 0.05% and DII 0.63% as of FY-2026 Q4 (most recent filed). Latest QoQ saw FII tick up +0.05pp and DII +0.40pp while promoter trimmed 1.23pp — a mild rebalance but no institutional capitulation. No bulk/block deals flagged. The low FII/DII presence means institutional conviction is not driving the stock; upside will come from earnings delivery, not multiple re-rating.
It is a cycle of development till to approved. And you have to undergo certain trials as well as certain performances, which have to be proven.
29%, 30% margins sustainable. Revenues growing, economies of scale showing. Technologies in-house, cost will go down.
1 · Kavach ISA certification milestone (Q3–Q4 FY27 or later)
Trials ongoing; management evasive on approval timeline. ISA sign-off unlocks ₹100–120 Cr order book realization. If slips into FY28, the 40–50% CAGR thesis falters.
2 · Fusion PCB utilization ramp (H2 FY27–FY28)
Initial 30–40% PCBA capacity. Rate of ramp-up signals confidence in internal demand (locomotive subsystems) + external customers. Plateau or slow ramp = execution doubt.
3 · Hydrogen propulsion system order execution (FY27–28)
₹3,100 HP locomotive delivery by next year. First hydrogen deployment after battery loco success. Delivery de-risks platform; delays flag supply chain or technical friction.
4 · International partnerships revenue conversion (FY27–28 onwards)
InnoTrans partnerships in motion. Management guided couple of million-dollar orders possible in current/next year. Track conversion pace to validate 1/4–1/2 global revenue by FY30 thesis.
Concord delivered a strong operational quarter — ₹159 Cr revenue (+95%), ₹846 Cr order book (4× annual), margin beat, and disciplined working capital. But the reported profit narrative (claiming 95% growth) doesn't square with the 80.2% actual: a sign that management is spinning the story, not just reporting it. The bull case is real, but execution-dependent: Kavach approval (₹100–120 Cr order), Fusion ramp (₹400 Cr target), hydrogen propulsion delivery (₹3,100 HP), and international partnerships (FY30 1/4–1/2 target) are all material and 12–24 months out.
The rating: Hold. The fundamentals are sound (order visibility, margin beat), but the platforms are early-stage, the regulatory approval is vague, and the customer concentration is high. A holder should stay the course on operational progress; a buyer should wait for one de-risking catalyst (Kavach approval or Fusion ramp-up confirmation) before averaging in.
The number to track: Order book execution rate (target ₹200–250 Cr annual run-rate) and EBITDA margin (watch for floor break below 28%).
95% revenue surge on record order book, but platforms early-stage
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Hit revenue target, beat margin guidance (29% vs 20-25%), order book upgraded mid-year (+₹149Cr to ₹846Cr); minor overstatement on profit growth % only
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Delivered a strong quarter (₹159Cr +95% revenue, 29% EBITDA margin, ₹846Cr order book) supported by railway electrification tailwinds and emerging green-mobility platforms. However, multiple growth engines (Kavach approval, Fusion integration, hydrogen propulsion) remain early-stage with uncertain execution timelines; management overstated PAT growth (claimed 95%, actual 80.2%).
₹159.1 Cr
Revenue · +95.1% YoY₹31.1 Cr
Reported PAT · +80.2% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Revenue grown ~95% YoY to ~159 crores
METDelivered 159.1 Cr, +95.1% YoY from ~81.6 Cr prior year
Profits up ~95% to 31.2 crores
OVERSTATEDDelivered 31.1 Cr, but grew only 80.2% YoY, not 95%
EBITDA margin 29.30%, up ~110% YoY to 46.7 crores
METMargin 29.34% (46.7/159.1); implies prior EBITDA ~21 Cr, supporting ~110% growth
Order book 846 crores as of 30-Sep-2026
METDerived: opening 697 + received 308 - executed 159 = 846 Cr, consistent with stated execution
Targeting 40-50% CAGR over next 3-5 years
METH1 FY27 at 95% growth trajectory, order book 846 Cr provides multi-year visibility
Earnings quality
What changed since the last call
Order book upgraded
UpgradeOrder book rose from ₹697Cr (FY26 guidance) to ₹846Cr (+₹149Cr) mid-H1, driven by new Kavach/hydrogen/green-mobility orders
EBITDA margin beat
UpgradeDelivered 29.3% vs prior guidance of 20-25%; economies of scale from order execution showing through faster than expected
Fusion integration live
NewFusion PCB acquisition now in production-ready state; contributing to cost structure and capability for flex/rigid PCB; expected ₹400Cr revenue at scale
Hydrogen propulsion order booked
NewOrder received for ₹3100HP hydrogen locomotive; execution by next year. First hydrogen propulsion deployment after battery loco success
The Q&A
Analysts pressed on Kavach approval timeline (mgmt evasive, said 'process ongoing'), Fusion market size (no number), margin floor (mgmt confident 29-30% sustainable). Management held ground on order-book strength and technology moats, but hedged specifics. Moderate pressure, not defensive.
Kavach approval — Shashank Jha
DodgedIt's a cycle of development till approved. Undergoing trials and performances, which have to be proven. Already progressing.
Progota consolidation — Shashank Jha
Answered46.5% stake. In associate, only profit consolidated to balance sheet, not revenue. Revenue is increasing without Kavach.
Green hydrogen order — Shubham Agarwal
AnsweredOrder received for green hydrogen-based propulsion system to be executed by next year.
Kavach execution risk — Chitresh Lunawat
PartialInstallation on loco and section ongoing. Difficult to give percentage; multiple equally important technologies in parallel.
Advanced Rail business — Pritesh Chheda
Answered>80% Advanced Rail business; 80% of future order book from locomotives and safety products. No more Advanced Rail as separate unit.
Margin sustainability — Mudit Jain
Answered29%, 30% margins sustainable. Revenues growing, economies of scale showing. Technologies in-house, cost will go down.
Fusion PCB capacity — Mudit Jain
Answered30-40% of PCBA capabilities utilized initially. Large installed capacity; only marginal percentage of rigid PCBs used. Multiple vendors already in discussion for supply agreements.
Kavach competition — Mudit Jain
AnsweredLarge 10-15 year opportunity. Railway Ministry making safety priority. Long approval gestation — even new entrants will take years. 10% only deployed till now; large pie unserved.
International partnerships — Shubham Agarwal
PartialLong-term opportunities. Couple of million-dollar orders possible in current/next year, but that's not the scale asked. By FY30, 1/4 to 1/2 global revenue expected; multi-year from partnerships.
FY27-28 revenue guidance — Pritesh Chheda
PartialH2 consistently higher than H1. H1 promising, will continue. 40-50% CAGR year-on-year target. Similar growth expected for Kavach also.
Guidance
40-50% CAGR over next 3-5 years (maintained from FY26 guidance)
HighBased on current order book (₹846Cr), technology roadmap (Fusion, Kavach, green mobility, hydrogen), and demonstrated H1 execution (95% growth). 3-5 year horizon means FY30-32 targets ~₹700-1000Cr revenue.
EBITDA margin 29-30% sustainable (upgraded from prior 20-25%)
MediumDelivered 29.3% in H1; management expects cost reduction from in-house technology (Fusion PCB, Kavach integration), but margin not expected to expand further. Economies of scale from order book will offset inflation.
Adequate cash flow from operations; no major fundraising required (stated on call)
MediumWorking capital improving; Fusion acquisition complete, so capex should moderate. Any major platform expansion (hydrogen propulsion manufacturing) may need debt/equity, but not flagged as urgent.
Risks the call surfaced
Regulatory approval
HighKavach requires ISA-certified trials before deployment; approval timeline vague. Delay would push revenue contribution to later years, impacting CAGR.
Technology execution
Medium₹3100HP hydrogen locomotive order received; execution by FY27-28. First-of-a-kind deployment; supply chain (fuel cell, tank) and integration risk.
Customer concentration
High80% of order book from Indian Railways and locomotive subsystems (Kavach, green mobility, propulsion). Limited diversification into adjacent sectors.
Integration risk
MediumFusion PCB acquisition integrated; target ₹400Cr revenue at scale. Initially only 30-40% PCBA capacity utilized; ramp-up depends on internal demand + external customers.
Revenue timing
MediumManagement targets 1/4 to 1/2 revenue from global markets by FY30. InnoTrans (Germany) partnerships positive, but conversion to orders is 'long-term' (multi-year). Risk of slower ramp than 40-50% CAGR assumes.
Management
Score 7/10. Transparent on order book and technology roadmap; vague on Kavach approval timeline and market sizing (Fusion, green mobility). Evasive on specific revenue guidance for FY27-28. Delivered ₹159Cr revenue (+95% YoY) against order book; improved working capital efficiency (debtor 210→178 days). Minor overstatement on PAT growth (claimed 95%, actual 80%) signals selective reporting.
1 · Q3/Q4 FY27
Kavach ISA certification milestone; trials ongoing, but approval timeline vague
2 · FY27-28
Hydrogen propulsion system order execution (₹3100 HP received); battery locomotive case study emerging
3 · H2 FY27
Fusion PCB production ramp-up; target 30-40% of PCBA capacity initially, scale to 400+ Cr revenue at full
However, multiple growth engines (Kavach approval, Fusion integration, hydrogen propulsion) remain early-stage with uncertain execution timelines; management overstated PAT growth (claimed 95%, actual 80.2%).
Concord Control H1 FY27 PAT +95% YoY to ₹31.2 Cr, revenue nearly doubles
PAT +94.95% YoY · revenue +95.12% · margins flat
₹159.11 Cr
+95.12% YoY
₹31.23 Cr
+94.95% YoY
19.38%
-1.4pp YoY
₹30.08
Concord Control Systems reported consolidated PAT (attributable to owners) of ₹31.23 Cr for H1 FY27 (half year ended 30-Sep-2026), up 94.95% YoY from ₹16.02 Cr in H1 FY26, on consolidated revenue from operations of ₹159.11 Cr, up 95.12% YoY from ₹81.55 Cr. Standalone tells a close but not identical story: standalone PAT of ₹32.86 Cr (+90.27% YoY) is nominally higher in absolute rupees than the consolidated attributable figure — the gap is explained by a ₹1.12 Cr consolidated share-of-loss from two equity-method associates (Progota India Private Ltd, Concord Lab to Market Innovations Private Ltd) plus higher consolidated operating costs, partly offset by a minority-interest credit of ₹0.13 Cr tied to subsidiary Fusion Electronics. Consolidated is the primary basis per our convention; standalone is the secondary read.
Q2 FY-2027 vs prior quarters
Margins were essentially flat YoY on the primary consolidated basis: net profit margin was 19.38% of total income versus 19.30% a year ago. EBITDA (PBT plus finance cost and depreciation) works out to roughly ₹46.7 Cr, a margin of about 29.3% of revenue — above the 20-25% EBITDA band management guided to at the Q4 FY26 concall (14-May-2026). Finance cost rose to ₹3.18 Cr consolidated from ₹0.54 Cr, and depreciation to ₹2.16 Cr from ₹1.09 Cr, both scaling with the balance sheet (short-term borrowings up to ₹70.97 Cr from ₹39.15 Cr at FY26-end), but neither dented the overall margin.
The stock went into the print at ₹2,433, up 4.8% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 5 consecutive quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
No exceptional/extraordinary items in either statement this half or the year-ago half — growth is organic, not one-off driven
Management is guiding for strong revenue growth, citing a 40-50% CAGR, supported by a record executable order book of INR 697 crores with an 18-24 month execution cycle. The company is targeting a realistic EBITDA margin of 20-25% while managing growth-related working capital needs. Strategically, the focus is on a maj
— This quarter: beat
No formal street/analyst estimates for this quarter could be located — Concord trades at a market cap in the low thousands of crores with limited broker coverage, so vsStreet is marked unknown rather than invented. Against management's own prior guidance (Q4 FY26 concall: 40-50% revenue CAGR off a then-record ₹697 Cr executable order book with an 18-24 month execution cycle, and a 20-25% EBITDA margin target), this print is a clear beat — ~95% YoY revenue growth is well ahead of the guided CAGR range, and the ~29% EBITDA margin sits above the guided band. No separate management press release was available for this filing (board outcome letter and the two Annexure statements plus limited-review reports were the only documents); the only this-quarter corporate markers on record are procedural — the 02-Nov-2026 board meeting that approved these results and a scheduled 29-Oct-2026 post-results concall, which should give the first direct management commentary on this print.
W1
Order-book execution: whether H2 FY27 conversion of the ₹697 Cr order book (18-24 month cycle, per Q4 FY26 concall) sustains the ~95% YoY growth pace toward the guided 40-50% CAGR
W2
Associate-entity losses: consolidated share of loss from Progota India and Concord Lab to Market Innovations was ₹1.12 Cr this half vs ₹1.25 Cr a year ago — watch for a turn to profitability
W3
EBITDA margin durability near ~29% (vs guided 20-25%) as receivables (₹140.76 Cr) and short-term borrowings (₹70.97 Cr) build with growth